Ser17
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser17  -  IKKG (human)

Site Information
LCEMVQPsGGPAADQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 50564412
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 , 4 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , lung cancer ( 2 , 3 , 4 ) , non-small cell lung cancer ( 2 , 4 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 ) , non-small cell large cell lung carcinoma ( 2 ) , non-small cell squamous cell lung carcinoma ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , 3T3 (fibroblast) ( 1 ) , DMS153 (pulmonary) ( 4 ) , HCC15 (pulmonary) ( 3 ) , LOU-NH91 (squamous) ( 3 ) , lung ( 2 , 3 , 4 ) , MCF-7 (breast cell) ( 1 ) , NCI-H1299 (pulmonary) ( 2 ) , NCI-H1437 (pulmonary) ( 4 ) , NCI-H1703 (squamous) ( 3 ) , NCI-H1734 (pulmonary) ( 2 ) , NCI-H1944 (pulmonary) ( 2 ) , NCI-H2073 (pulmonary) ( 3 , 4 ) , NCI-H209 (pulmonary) ( 4 ) , NCI-H2342 (pulmonary) ( 3 ) , NCI-H358 (pulmonary) ( 2 ) , NCI-H460 (pulmonary) ( 2 ) , NCI-H838 (pulmonary) ( 4 )

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 1 )
Kinases, in vitro:
GSK3B (human) ( 1 )

Downstream Regulation
Effects of modification on IKKG:
protein stabilization ( 1 )
Effects of modification on biological processes:
transcription, induced ( 1 )

References 

1

Medunjanin S, et al. (2016) GSK-3β controls NF-kappaB activity via IKKγ/NEMO. Sci Rep 6, 38553
27929056   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info